NASDAQ:CERE

Cerevel Therapeutics (CERE) Stock Forecast, Price & News

$20.35

+0.09 (+0.44%)

(As of 09/25/2023 ET)

Compare

Today's Range: $19.85
▼
$20.42
50-Day Range: $20.26
▼
$30.73
52-Week Range: $19.85
▼
$35.98

Volume: 806,648 shs
Average Volume: 615,277 shs
Market Capitalization: $3.20 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.00

Cerevel Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 67.1% Upside
$34.00 Price Target
Short Interest: Bearish
7.92% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.10
Based on 4 Articles This Week
Insider Trading: Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth: Decreasing
From ($2.59) to ($2.70) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

Medical Sector

866th out of 963 stocks

Pharmaceutical Preparations Industry

405th out of 447 stocks

3.3

Analyst's Opinion

Consensus Rating
Cerevel Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $34.00, Cerevel Therapeutics has a forecasted upside of 67.1% from its current price of $20.35.
Amount of Analyst Coverage
Cerevel Therapeutics has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.92% of the float of Cerevel Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Cerevel Therapeutics has a short interest ratio ("days to cover") of 8.6.
Change versus previous month
Short interest in Cerevel Therapeutics has recently increased by 7.09%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cerevel Therapeutics does not currently pay a dividend.
Dividend Growth
Cerevel Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CERE.

1.1

News and Social Media Coverage

News Sentiment
Cerevel Therapeutics has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Cerevel Therapeutics this week, compared to 3 articles on an average week.
MarketBeat Follows
Only 1 people have added Cerevel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cerevel Therapeutics insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $2,510,922.00 in company stock and sold $2,705,000.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.
Percentage Held by Insiders
Only 5.10% of the stock of Cerevel Therapeutics is held by insiders.
Percentage Held by Institutions
87.73% of the stock of Cerevel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.59) to ($2.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cerevel Therapeutics is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cerevel Therapeutics is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cerevel Therapeutics has a P/B Ratio of 6.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cerevel Therapeutics (NASDAQ:CERE) Stock

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

CERE Price History

30 days | 90 days | 365 days | Advanced Chart

CERE Stock News Headlines

September 24, 2023 | americanbankingnews.com

Cerevel Therapeutics (NASDAQ:CERE) Stock Price Down 3.2%

September 22, 2023 | benzinga.com

Parkinson's Disease Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)

September 26, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

September 22, 2023 | americanbankingnews.com

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Receives Average Recommendation of "Moderate Buy" from Analysts

September 12, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), ADC Therapeutics (ADCT) and Sanofi (OtherSNYNF)

September 8, 2023 | benzinga.com

Cannabis Odor Sparks Legal Battle Impacting California Real Estate, Lawsuit Alleges Nuisance

August 29, 2023 | finance.yahoo.com

Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

August 25, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Catalent (CTLT)

September 26, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

August 23, 2023 | bizjournals.com

J&J-backed startup raises $150M in VC for neuroscience drugs

August 11, 2023 | finance.yahoo.com

Insiders Buy the Dip in These 2 Beaten-Down Stocks, Analysts Say They Could Be Ready to Bounce Back — Here’s Why You Should Pay Attention

August 9, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Revance Therapeutics (RVNC), Personalis (PSNL)

August 6, 2023 | markets.businessinsider.com

Stifel Nicolaus Keeps Their Buy Rating on Cerevel Therapeutics Holdings (CERE)

August 5, 2023 | benzinga.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE

August 4, 2023 | msn.com

Cerevel: Drop On Data Delay For EMPOWER Program Provides Buy Opportunity

August 3, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Cerevel Therapeutics Holdings (CERE), G1 Therapeutics (GTHX)

August 3, 2023 | msn.com

Why Is Cerevel Therapeutics Stock Trading Lower Today?

August 3, 2023 | seekingalpha.com

Cerevel Therapeutics falls on delayed data readouts

August 3, 2023 | markets.businessinsider.com

Cerevel Therapeutics Holdings (CERE) Receives a Hold from Berenberg Bank

August 3, 2023 | msn.com

Cerevel Therapeutics falls on delayed readout

August 2, 2023 | msn.com

Cerevel Therapeutics GAAP EPS of -$0.63 beats by $0.06

August 2, 2023 | fool.com

Why Shares of Cerevel Therapeutics Are Dropping Wednesday

August 2, 2023 | finance.yahoo.com

Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

July 11, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Viridian Therapeutics (VRDN), Arbutus Biopharma (ABUS)

July 7, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Ambrx Biopharma (AMAM)

July 5, 2023 | finance.yahoo.com

Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023

June 20, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Calliditas Therapeutics (CALT), Surface Oncology (SURF) and Crinetics Pharmaceuticals (CRNX)

See More Headlines

Receive CERE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CERE Company Calendar

Last Earnings: 8/02/2023
Today: 9/26/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Coal & Consumable Fuels
Sector: Medical
Current Symbol: NASDAQ:CERE
CUSIP: 15677310
CIK: 767884
Web: ceres.net
Phone: 844-304-2048
Fax: N/A
Employees: 322
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $34.00
High Stock Price Forecast: $46.00
Low Stock Price Forecast: $22.00
Forecasted Upside/Downside: +67.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-351,510,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -83.19%
Return on Assets: -40.30%

Debt

Debt-to-Equity Ratio: 0.96
Current Ratio: 11.47
Quick Ratio: 11.47

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.33 per share
Price / Book: 6.11

Miscellaneous

Outstanding Shares: 157,490,000
Free Float: 149,456,000
Market Cap: $3.20 billion
Optionable: Not Optionable
Beta: 1.42

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. N. Anthony Coles Jr. (Age 63)
M.P.H., Exec. Chairman
Comp: $1.14M

Mr. Mark Bodenrader (Age 50)
VP of Fin. & Chief Accounting Officer
Comp: $496.17k

Dr. John J. Renger Ph.D. (Age 54)
Chief Scientific Officer
Comp: $779.75k

Dr. Ramiro Sanchez M.D. (Age 62)
Chief Medical Officer
Comp: $805.13k

Mr. Ronald C. Renaud Jr. (Age 54)
M.B.A., MBA, Pres, CEO & Director

Dr. Susan Altschuller M.B.A. (Age 41)
Ph.D., Chief Financial Officer

Mr. Matthew Calistri
VP of Investor Relations

Mr. Scott M. Akamine J.D. (Age 38)
Chief Legal Officer & Corp. Sec.

Mr. Kenneth A. DiPietro (Age 64)
Chief HR Officer

Ms. Kathleen Tregoning M.A. (Age 52)
Chief Corp. Affairs Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CERE Stock - Frequently Asked Questions

Should I buy or sell Cerevel Therapeutics stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CERE shares.
View CERE analyst ratings or view top-rated stocks.
What is Cerevel Therapeutics' stock price forecast for 2023?: 10 equities research analysts have issued 12-month price objectives for Cerevel Therapeutics' shares. Their CERE share price forecasts range from $22.00 to $46.00. On average, they expect the company's stock price to reach $34.00 in the next twelve months. This suggests a possible upside of 67.1% from the stock's current price.
View analysts price targets for CERE or view top-rated stocks among Wall Street analysts.
How have CERE shares performed in 2023?: Cerevel Therapeutics' stock was trading at $31.54 on January 1st, 2023. Since then, CERE stock has decreased by 35.5% and is now trading at $20.35.
View the best growth stocks for 2023 here.
Are investors shorting Cerevel Therapeutics?: Cerevel Therapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 5,440,000 shares, an increase of 7.1% from the August 15th total of 5,080,000 shares. Based on an average daily volume of 635,600 shares, the short-interest ratio is currently 8.6 days. Currently, 7.9% of the company's shares are sold short.
View Cerevel Therapeutics' Short Interest.
When is Cerevel Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our CERE earnings forecast.
How were Cerevel Therapeutics' earnings last quarter?: Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) posted its earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.02. During the same quarter in the previous year, the firm earned ($0.61) EPS.
What ETFs hold Cerevel Therapeutics' stock?: ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), iShares Neuroscience and Healthcare ETF (IBRN), Principal Healthcare Innovators ETF (BTEC), Harbor Health Care ETF (MEDI) and Fidelity Disruptive Medicine ETF (FMED).

What other stocks do shareholders of Cerevel Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO).
What is Cerevel Therapeutics' stock symbol?: Cerevel Therapeutics trades on the NASDAQ under the ticker symbol "CERE."
Who are Cerevel Therapeutics' major shareholders?: Cerevel Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (6.41%), BlackRock Inc. (3.08%), State Street Corp (1.76%), Artal Group S.A. (1.04%), Geode Capital Management LLC (0.86%) and Polar Capital Holdings Plc (0.58%). Insiders that own company stock include Abraham Ceesay, Deval L Patrick, Gabrielle Sulzberger, John Renger, Marijn E Dekkers, Mark Bodenrader, N Anthony Coles, Paul D Burgess, Perceptive Advisors Llc and Ronald C Renaud Jr.
View institutional ownership trends.
How do I buy shares of Cerevel Therapeutics?: Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cerevel Therapeutics' stock price today?: One share of CERE stock can currently be purchased for approximately $20.35.
How much money does Cerevel Therapeutics make?: Cerevel Therapeutics (NASDAQ:CERE) has a market capitalization of $3.20 billion. The biotechnology company earns $-351,510,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.
How many employees does Cerevel Therapeutics have?: The company employs 322 workers across the globe.
How can I contact Cerevel Therapeutics?: Cerevel Therapeutics' mailing address is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. The official website for the company is ceres.net. The biotechnology company can be reached via phone at 844-304-2048 or via email at ir@cerevel.com.

This page (NASDAQ:CERE) was last updated on 9/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial